2024-10-012025-09-302025-09-30false09224293MEDICUSLEX LIMITED2026-05-13falseiso4217:GBPxbrli:pure092242932024-09-30092242932025-09-30092242932024-10-012025-09-30092242932023-09-30092242932024-09-30092242932023-10-012024-09-3009224293bus:SmallEntities2024-10-012025-09-3009224293bus:AuditExempt-NoAccountantsReport2024-10-012025-09-3009224293bus:FullAccounts2024-10-012025-09-3009224293bus:PrivateLimitedCompanyLtd2024-10-012025-09-3009224293core:WithinOneYear2025-09-3009224293core:AfterOneYear2025-09-3009224293core:WithinOneYear2024-09-3009224293core:AfterOneYear2024-09-3009224293core:ShareCapital2025-09-3009224293core:SharePremium2025-09-3009224293core:RevaluationReserve2025-09-3009224293core:OtherReservesSubtotal2025-09-3009224293core:RetainedEarningsAccumulatedLosses2025-09-3009224293core:ShareCapital2024-09-3009224293core:SharePremium2024-09-3009224293core:RevaluationReserve2024-09-3009224293core:OtherReservesSubtotal2024-09-3009224293core:RetainedEarningsAccumulatedLosses2024-09-3009224293core:LandBuildings2025-09-3009224293core:PlantMachinery2025-09-3009224293core:Vehicles2025-09-3009224293core:FurnitureFittings2025-09-3009224293core:OfficeEquipment2025-09-3009224293core:NetGoodwill2025-09-3009224293core:IntangibleAssetsOtherThanGoodwill2025-09-3009224293core:ListedExchangeTraded2025-09-3009224293core:UnlistedNon-exchangeTraded2025-09-3009224293core:LandBuildings2024-09-3009224293core:PlantMachinery2024-09-3009224293core:Vehicles2024-09-3009224293core:FurnitureFittings2024-09-3009224293core:OfficeEquipment2024-09-3009224293core:NetGoodwill2024-09-3009224293core:IntangibleAssetsOtherThanGoodwill2024-09-3009224293core:ListedExchangeTraded2024-09-3009224293core:UnlistedNon-exchangeTraded2024-09-3009224293core:LandBuildings2024-10-012025-09-3009224293core:PlantMachinery2024-10-012025-09-3009224293core:Vehicles2024-10-012025-09-3009224293core:FurnitureFittings2024-10-012025-09-3009224293core:OfficeEquipment2024-10-012025-09-3009224293core:NetGoodwill2024-10-012025-09-3009224293core:IntangibleAssetsOtherThanGoodwill2024-10-012025-09-3009224293core:ListedExchangeTraded2024-10-012025-09-3009224293core:UnlistedNon-exchangeTraded2024-10-012025-09-3009224293core:MoreThanFiveYears2024-10-012025-09-3009224293core:Non-currentFinancialInstruments2025-09-3009224293core:Non-currentFinancialInstruments2024-09-3009224293dpl:CostSales2024-10-012025-09-3009224293dpl:DistributionCosts2024-10-012025-09-3009224293core:LandBuildings2024-10-012025-09-3009224293core:PlantMachinery2024-10-012025-09-3009224293core:Vehicles2024-10-012025-09-3009224293core:FurnitureFittings2024-10-012025-09-3009224293core:OfficeEquipment2024-10-012025-09-3009224293dpl:AdministrativeExpenses2024-10-012025-09-3009224293core:NetGoodwill2024-10-012025-09-3009224293core:IntangibleAssetsOtherThanGoodwill2024-10-012025-09-3009224293dpl:GroupUndertakings2024-10-012025-09-3009224293dpl:ParticipatingInterests2024-10-012025-09-3009224293dpl:GroupUndertakingscore:ListedExchangeTraded2024-10-012025-09-3009224293core:ListedExchangeTraded2024-10-012025-09-3009224293dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-10-012025-09-3009224293core:UnlistedNon-exchangeTraded2024-10-012025-09-3009224293dpl:CostSales2023-10-012024-09-3009224293dpl:DistributionCosts2023-10-012024-09-3009224293core:LandBuildings2023-10-012024-09-3009224293core:PlantMachinery2023-10-012024-09-3009224293core:Vehicles2023-10-012024-09-3009224293core:FurnitureFittings2023-10-012024-09-3009224293core:OfficeEquipment2023-10-012024-09-3009224293dpl:AdministrativeExpenses2023-10-012024-09-3009224293core:NetGoodwill2023-10-012024-09-3009224293core:IntangibleAssetsOtherThanGoodwill2023-10-012024-09-3009224293dpl:GroupUndertakings2023-10-012024-09-3009224293dpl:ParticipatingInterests2023-10-012024-09-3009224293dpl:GroupUndertakingscore:ListedExchangeTraded2023-10-012024-09-3009224293core:ListedExchangeTraded2023-10-012024-09-3009224293dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-10-012024-09-3009224293core:UnlistedNon-exchangeTraded2023-10-012024-09-3009224293core:NetGoodwill2025-09-3009224293core:IntangibleAssetsOtherThanGoodwill2025-09-3009224293core:LandBuildings2025-09-3009224293core:PlantMachinery2025-09-3009224293core:Vehicles2025-09-3009224293core:FurnitureFittings2025-09-3009224293core:OfficeEquipment2025-09-3009224293core:AfterOneYear2025-09-3009224293core:WithinOneYear2025-09-3009224293core:ListedExchangeTraded2025-09-3009224293core:UnlistedNon-exchangeTraded2025-09-3009224293core:ShareCapital2025-09-3009224293core:SharePremium2025-09-3009224293core:RevaluationReserve2025-09-3009224293core:OtherReservesSubtotal2025-09-3009224293core:RetainedEarningsAccumulatedLosses2025-09-3009224293core:NetGoodwill2024-09-3009224293core:IntangibleAssetsOtherThanGoodwill2024-09-3009224293core:LandBuildings2024-09-3009224293core:PlantMachinery2024-09-3009224293core:Vehicles2024-09-3009224293core:FurnitureFittings2024-09-3009224293core:OfficeEquipment2024-09-3009224293core:AfterOneYear2024-09-3009224293core:WithinOneYear2024-09-3009224293core:ListedExchangeTraded2024-09-3009224293core:UnlistedNon-exchangeTraded2024-09-3009224293core:ShareCapital2024-09-3009224293core:SharePremium2024-09-3009224293core:RevaluationReserve2024-09-3009224293core:OtherReservesSubtotal2024-09-3009224293core:RetainedEarningsAccumulatedLosses2024-09-3009224293core:NetGoodwill2023-09-3009224293core:IntangibleAssetsOtherThanGoodwill2023-09-3009224293core:LandBuildings2023-09-3009224293core:PlantMachinery2023-09-3009224293core:Vehicles2023-09-3009224293core:FurnitureFittings2023-09-3009224293core:OfficeEquipment2023-09-3009224293core:AfterOneYear2023-09-3009224293core:WithinOneYear2023-09-3009224293core:ListedExchangeTraded2023-09-3009224293core:UnlistedNon-exchangeTraded2023-09-3009224293core:ShareCapital2023-09-3009224293core:SharePremium2023-09-3009224293core:RevaluationReserve2023-09-3009224293core:OtherReservesSubtotal2023-09-3009224293core:RetainedEarningsAccumulatedLosses2023-09-3009224293core:AfterOneYear2024-10-012025-09-3009224293core:WithinOneYear2024-10-012025-09-3009224293core:Non-currentFinancialInstrumentscore:CostValuation2024-10-012025-09-3009224293core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-10-012025-09-3009224293core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-10-012025-09-3009224293core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-10-012025-09-3009224293core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-10-012025-09-3009224293core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-10-012025-09-3009224293core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-10-012025-09-3009224293core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-10-012025-09-3009224293core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-10-012025-09-3009224293core:Non-currentFinancialInstrumentscore:CostValuation2025-09-3009224293core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-09-3009224293core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-09-3009224293core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-09-3009224293core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-09-3009224293core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-09-3009224293core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-09-3009224293core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-09-3009224293core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-09-3009224293core:Non-currentFinancialInstrumentscore:CostValuation2024-09-3009224293core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-09-3009224293core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-09-3009224293core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-09-3009224293core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-09-3009224293core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-09-3009224293core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-09-3009224293core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-09-3009224293core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-09-3009224293bus:Director12024-10-012025-09-3009224293bus:Director22024-10-012025-09-3009224293core:FurnitureFittingsToolsEquipment2024-09-3009224293core:FurnitureFittingsToolsEquipment2024-10-012025-09-3009224293core:FurnitureFittingsToolsEquipment2025-09-30

MEDICUSLEX LIMITED

Registered Number
09224293
(England and Wales)

Unaudited Financial Statements for the Year ended
30 September 2025

MEDICUSLEX LIMITED
Company Information
for the year from 1 October 2024 to 30 September 2025

Directors

DANBURY, Catriona Luise
DANBURY, Christopher Michael, Dr

Registered Address

Faulkner House
31 West Street
Wimborne
BH21 1JS

Registered Number

09224293 (England and Wales)
MEDICUSLEX LIMITED
Balance Sheet as at
30 September 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets3112,37336,956
112,37336,956
Current assets
Debtors4105,79387,414
Current asset investments515,001-
Cash at bank and on hand47,36062,826
168,154150,240
Creditors amounts falling due within one year6(99,590)(104,118)
Net current assets (liabilities)68,56446,122
Total assets less current liabilities180,93783,078
Creditors amounts falling due after one year7(70,921)(19,912)
Net assets110,01663,166
Capital and reserves
Called up share capital150150
Profit and loss account109,86663,016
Shareholders' funds110,01663,166
The financial statements were approved and authorised for issue by the Board of Directors on 13 May 2026, and are signed on its behalf by:
DANBURY, Catriona Luise
Director
DANBURY, Christopher Michael, Dr
Director

Registered Company No. 09224293
MEDICUSLEX LIMITED
Notes to the Financial Statements
for the year ended 30 September 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Going concern
After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis of accounting in preparing its financial statements.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:
Investments
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
Finance leases and hire purchase contracts
Assets held under finance leases which are leases where substantially all the risks and rewards of ownership of the asset have passed to the company, and hire purchase contracts are capitalised in the balance sheet. They are depreciated over the shorter of their useful lives or the term of the lease.
2.Average number of employees

20252024
Average number of employees during the year32
3.Tangible fixed assets

Plant & machinery

Vehicles

Fixtures & fittings

Office Equipment

Total

£££££
Cost or valuation
At 01 October 24-89,3079,85431,613130,774
Additions1,83393,455-6,026101,314
Disposals-(47,990)--(47,990)
At 30 September 251,833134,7729,85437,639184,098
Depreciation and impairment
At 01 October 24-60,5005,83427,48493,818
Charge for year1985,1981,0054,31110,712
On disposals-(32,805)--(32,805)
At 30 September 2519832,8936,83931,79571,725
Net book value
At 30 September 251,635101,8793,0155,844112,373
At 30 September 24-28,8074,0204,12936,956
4.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables105,53887,414
Prepayments and accrued income255-
Total105,79387,414
5.Current asset investments
6.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables1,5872,578
Taxation and social security89,60597,522
Finance lease and HP contracts4,629-
Other creditors9681,167
Accrued liabilities and deferred income2,8012,851
Total99,590104,118
7.Creditors: amounts due after one year

2025

2024

££
Bank borrowings and overdrafts-19,912
Other creditors70,921-
Total70,92119,912
8.Obligations under finance leases

2025

2024

££
Finance lease and HP contracts75,550-